Last reviewed 2026-05-25 · How we verify

Emonapride (NEMONAPRIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Emonapride (generic name: NEMONAPRIDE) is a nemonapride drug. It is currently in Phase 2 development.

Emonapride works by blocking the D(4) dopamine receptor, which can help to reduce excessive dopamine activity in the brain.

Emonapride is a small molecule. Its mechanism of action is not specified in the provided information.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NEMONAPRIDE
Drug class	nemonapride
Target	D(4) dopamine receptor, Transmembrane protein 97, D(2) dopamine receptor
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is like a city with many different streets. Dopamine is like a busy highway that carries important messages. When there's too much traffic on this highway, it can cause problems. Emonapride is like a traffic cop that blocks the highway, reducing the amount of traffic and helping to calm things down.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Emonapride CI brief — competitive landscape report
Emonapride updates RSS · CI watch RSS

Frequently asked questions about Emonapride

What is Emonapride?

Emonapride (NEMONAPRIDE) is a nemonapride drug.

How does Emonapride work?

Emonapride works by blocking the D(4) dopamine receptor, which can help to reduce excessive dopamine activity in the brain.

What is the generic name of Emonapride?

NEMONAPRIDE is the generic (nonproprietary) name of Emonapride.

What drug class is Emonapride in?

Emonapride belongs to the nemonapride class. See all nemonapride drugs at /class/nemonapride.

What development phase is Emonapride in?

Emonapride is in Phase 2.

What does Emonapride target?

Emonapride targets D(4) dopamine receptor, Transmembrane protein 97, D(2) dopamine receptor and is a nemonapride.

Drug class: All nemonapride drugs
Target: All drugs targeting D(4) dopamine receptor, Transmembrane protein 97, D(2) dopamine receptor
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing